Tumor microenvironment: an evil nexus promoting aggressive head and neck squamous cell carcinoma and avenue for targeted therapy  

作　　者：Ajaz A.Bhat Parvaiz Yousuf Nissar A.Wani Arshi Rizwan Shyam S.Chauhan Mushtaq A.Siddiqi Davide Bedognetti Wael EI-Rifai Michael P.Frenneaux Surinder K.Batra Mohammad Haris Muzafar A.Macha 

机构地区：[1]Functional and Molecular Imaging Laboratory,Cancer Research Department,Sidra Medicine,Doha,Qatar [2]Department of Zoology,School of Life Sciences,Central University of Kashmir,Ganderbal,Jammu&Kashmir,India [3]Department of Nephrology,All India Institute of Medical Sciences,New Delhi,India [4]Department of Biochemistry,All India Institute of Medical Sciences,New Delhi,India [5]Watson-Crick Centre for Molecular Medicine,Islamic University of Science and Technology,Awantipora,Jammu&Kashmir,India [6]Laboratory of Cancer Immunogenomics,Cancer Research Department,Sidra Medicine,Doha,Qatar [7]Department of Surgery,University of Miami,Miami,FL,USA [8]Academic Health System,Hamad Medical Corporation,Doha,Qatar [9]Department of Biochemisty and Molecular Biology,University of Nebraska Medical Center,Omaha,NE,USA [10]Eppley Institute for Research in Cancer and Alied Diseases,University of Nebraska Medical Center,Omaha,NE,USA [11]Buffet Cancer Center,University of Nebraska Medical Center,Omaha,NE,USA [12]Laboratory Animal Research Center,Qatar University,Doha,Qatar

出　　处：《Signal Transduction and Targeted Therapy》2021年第2期324-338,共15页信号转导与靶向治疗（英文）

基　　金：This study was supported by Ramalingaswami Fellowship(Grant number:D.O.NO.BT/HRD/35/02/2006)from the Department of Biotechnology,Government of India,New Delhi to Muzafar A.Macha;Mohammad Haris is funded by a grant(5071012001)from Sidra Medicine Doha,Qatar;Ajaz A.Bhat is supported by Sidra Medicine internal grant(5011041002).We thank Dr.Vineeta Tanwar(Ohio State University,Columbus,Ohio,USA)for her professional assistance in editing the paper.

摘　　要：Head and neck squamous cell carcinoma(HNSCC)is a very aggressive disease with a poor prognosis for advanced-stage tumors.Recent clinical,genomic,and cellular studies have revealed the highly heterogeneous and immunosuppressive nature of HNSCC.Despite signifcant advances in multimodal therapeutic interventions,failure to cure and recurrence are common and account for most deaths.It is becoming increasingly apparent that tumor microenvironment(TME)plays a critical role in HNSCC tumorigenesis,promotes the evolution of aggressive tumors and resistance to therapy,and thereby adversely affects the prognosis.A complete understanding of the TME factors,together with the highly complex tumor-stromal interactions,can lead to new therapeutic interventions in HNSCC.Interestingly,different molecular and immune landscapes between HPV^(+ve) and HPV^(-ve)(human papillomavirus)HNSCC tumors offer new opportunities for developing individualized,targeted chemoimmunotherapy(CIT)regimen.This review highlights the current understanding of the complexity between HPV^(+ve) and HPV^(-ve) HNSCC TME and various tumor-stromal cross-talk modulating processes,including epithelial-mesenchymal transition(EMT),anoikis resistance,angiogenesis,immune surveillance,metastatic niche,therapeutic resistance,and development of an aggressive tumor phenotype.Furthermore,we summarize the recent developments and the rationale behind CIT strategies and their clinical applications in HPV^(+ve) and HPV^(-ve) HNSCC.

关 键 词：TARGETED SQUAMOUS thereby 

分 类 号：R739.91[医药卫生—肿瘤]